Oakland, CA – According to filings with the U.S. Securities and Exchange Commission, Saccharo is raising $10,629,329.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Sheryl Martin-Moe played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Saccharo
Saccharo is a biotech company in pursuit of a novel polysaccharide oncology target found abundantly and specifically on the surface of cancer cells. Existing cancer drug targets are typically protein enriched, but not uniquely expressed on cancer cells. The lack of cancer specificity can result in off-target toxicity and damaging side effects. Additionally, patients can develop resistance to treatment because the protein target mutates, rendering the drug ineffective. Saccharos novel polysaccharide target (dPSA) is highly conserved, uniquely expressed on cancer cells, but not on normal cells. Antibodies or other drugs that target dPSA will selectively and consistently kill cancer cells potentially as a potent mono-therapy with superior safety.

To learn more about Saccharo, visit http://www.saccharo.com/

Contact:
Sheryl Martin-Moe, Chief Executive Officer
510-219-6741
https://www.linkedin.com/in/sherrymartinmoe/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved